vimarsana.com

Page 38 - காப்புரிமை பெற்றது மருந்துகள் ஒழுங்குமுறைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tracking AI Prosecution Trends At The U S Patent Office - Intellectual Property

XORTX Therapeutics Inc : XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection

XORTX Therapeutics Inc.: XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection CALGARY, AB / ACCESSWIRE / March 8, 2021 / XORTX Therapeutics Inc. XORTX or the Company ) (CSE:XRX) (OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, with late-stage clinical programs, is pleased to announce the filing of a new provisional patent application entitled Compositions and Methods for Enhancing Anti-Viral Therapies . This provisional patent was filed with the US Patent Office on Friday, March 5, 2021. In addition, studies of Coronavirus infections show that SARS and MERS and specifically COVID-19 can be frequently accompanied by pneumonia, acute kidney injury, proteinuria and hematuria

Sanctions Imposed Against Litigant For

Micro Focus: Jury Delivers Verdict In Favour Of Wapp In Patent Litigation Case

Micro Focus: Jury Delivers Verdict In Favour Of Wapp In Patent Litigation Case LONDON (dpa-AFX) - Micro Focus International plc (MCFUF.PK, MCRO.L) issued an update regarding its patent litigation with Wapp Tech Limited Partnership and Wapp Tech Corp. In 2018, Wapp brought a claim against Micro Focus in the Eastern District of Texas, accusing the company of infringing claims of three patents. On 5 March 2021, the jury has delivered a verdict in favour of the claimant and awarded damages totalling $172.5 million. The Group noted that the matter is awaiting the judge to hand down his judgement. Micro Focus intends to appeal any judgement resulting from the verdict.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.